Clincosm LogoSign in Get a demo

Double Blind Trial in Children With Autism Spectrum Disorder

Sponsor
Paxmedica (Industry)
Overall Status
Completed
CT.gov ID
NCT06058962
Collaborator
(none)
52
Enrollment
1
Location
3
Arms
21.5
Actual Duration (Months)
2.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study investigated the safe and efficacious use of suramin as a novel treatment for ASD by testing two suramin doses vs placebo

Condition or Disease Intervention/Treatment Phase
  • Drug: Suramin Sodium
 Phase 2

Detailed Description

PUR-ONQ-ASD-001 was a multicenter, 3-arm, prospective, randomized, double blind, placebo-controlled multiple dose trial involving 2 dose levels of suramin vs. placebo. The study randomized 52 male participants who received treatment interventions for ASD; each treatment arm was assigned approximately 17 participants. The number of participants was increased to 52 participants (48 originally planned) due to early withdrawals related to the COVID-19 global pandemic lockdowns and other matters. Participants were stratified by age, ADOS-2, and Non-verbal Intelligence Quotient (NVIQ). Participants who met all the inclusion criteria and none of the exclusion criteria were randomized through an electronic system to either arm A (10 mg/kg suramin) or Arm B (20 mg/kg suramin) or Arm C (Placebo) in a targeted 1:1:1 ratio, as per the randomization schedule and stratified by age, ADOS-2, and NVIQ. All participants received a 50 mg test dose at their first administration (0.5 mL of freshly reconstituted 10% solution in 5 mL saline) to check for allergic reactions. The test dose was given by slow intravenous (IV) infusion for 30 minutes then flushed with 10 mL saline. Vitals were checked for 30 min and if there were no changes or evidence of allergic reaction, the rest of the study drug dose was administered (10 mg/kg or 20 mg/kg minus test dose [minus 50 mg] in a 50 mL saline up to a maximum of 1 g given over 30 minutes). Arm A - 50 mg test dose of suramin (upon first administration), then suramin 10 mg/kg (minus 50 mg suramin test dose) in 50 mL of saline administered by IV infusion over 30 minutes was given at Visits 2, 4 and 5. The maximum dose administered was 1 g.

Arm B - 50 mg test dose of suramin (upon first administration), then suramin 20 mg/kg (minus 50 mg suramin test dose) in 50 mL of saline administered by IV infusion over 30 minutes was given at Visits 2, 4 and 5. The maximum dose administered was 1 g.

Arm C - Test dose of saline placebo, then saline placebo IV infusion of 50 mL administered over 30 minutes was given at Visits 2, 4 and 5

Study Design

Study Type:
Interventional
Actual Enrollment :
52 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The participants were randomized to one of three double-blind treatment groups, i.e., Arm A (10 mg/kg suramin) or Arm B (20 mg/kg suramin) or Arm C (placebo) in a targeted 1:1:1 ratio, as per the randomization schedule and stratification plan. The stratification plan was to match patients by age (< 7 vs ≥ 7), ADOS-2 comparison scores (≤ 8.5 vs > 8.5) and NVIQ (≤ 80 vs > 80)The participants were randomized to one of three double-blind treatment groups, i.e., Arm A (10 mg/kg suramin) or Arm B (20 mg/kg suramin) or Arm C (placebo) in a targeted 1:1:1 ratio, as per the randomization schedule and stratification plan. The stratification plan was to match patients by age (< 7 vs ≥ 7), ADOS-2 comparison scores (≤ 8.5 vs > 8.5) and NVIQ (≤ 80 vs > 80)
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
The study was double-blind. Suramin and placebo are both clear solutions when prepared. Suramin was prepared by an unblinded pharmacist by reconstituting 1 g vial of suramin in 10 mL of sterile water for infusion to prepare a 10% (100 mg/mL) solution.
Primary Purpose:
Treatment
Official Title:
A Three-Arm, Prospective, Randomized, Double Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of 2 Doses of Suramin vs. Placebo in Male Children With ASD Receiving Standard Treatment
Actual Study Start Date :
Jun 1, 2019
Actual Primary Completion Date :
Jan 15, 2021
Actual Study Completion Date :
Mar 15, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Arm A

50 mg test dose of suramin (upon first administration), then suramin 10 mg/kg (minus 50 mg suramin test dose) in 50 mL of saline administered by IV infusion over 30 minutes was given at Visits 2, 4, and 5.

Drug: Suramin Sodium
Suramin sodium is a sodium salt form of suramin, an antitrypanosomal compound.
Other Names:
  • Placebo

    		•
    Experimental: Arm B

    50 mg test dose of suramin (upon first administration), then suramin 20 mg/kg (minus 50 mg suramin test dose) in 50 mL of saline administered by IV infusion over 30 minutes was given at Visits 2, 4, and 5.

    Drug: Suramin Sodium
    Suramin sodium is a sodium salt form of suramin, an antitrypanosomal compound.
    Other Names:
  • Placebo

    		•
    Placebo Comparator: Arm C

    Test dose of saline placebo, then saline placebo infusion of 50 mL administered over 30 minutes was given at Visits 2, 4, and 5.

    Drug: Suramin Sodium
    Suramin sodium is a sodium salt form of suramin, an antitrypanosomal compound.
    Other Names:
  • Placebo

    		•

    Outcome Measures

    Primary Outcome Measures

    1. The primary objective was to evaluate the safety and efficacy of 2 dose levels of low dose suramin against placebo in children with ASD receiving standard treatment. [98 Days]

      ABC-Core and CGI-I scales used to evaluate efficacy

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    4 Years to 17 Years
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Male children aged 4 - 17 years

    • Participants with or without treatment interventions for ASD

    • Participants must have been diagnosed with ASD by Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V)

    • Autism diagnostic observation schedule, version 2 (ADOS-2) Comparison scores in the

    • moderate and high level as evaluated on the ADOS-2

    • Stable treatment intervention for ≥ 2 months

    • Participants agreed to not change their treatment interventions throughout the study

    • duration

    • Participants on Ritalin and Risperdal or similar medication agreed to not change their

    • dose during the study

    Exclusion Criteria:

    • Hospitalization within the previous 2 months

    • An acute medical problem, Rett syndrome, microcephaly, tuberous sclerosis, neurofibromatosis, epilepsy, or clinically significant liver, kidney, or adrenal disease or persons suffering from any serious acute condition where, in the investigator's opinion, the participant's well-being may have been compromised

    • Planning to start a new drug, diet, or behavioral intervention during the study

    • Weight under the 5th percentile for age

    • Unable to tolerate venipuncture, urine collection, or an indwelling IV catheter for 3-4 hours

    • Plasma creatinine above normal for age and weight according to the laboratory reference ranges.

    • Liver function alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 1.5-fold above the upper limit of normal

    • Known intolerance to suramin or other antipurinergic drugs

    • Unable to perform or cooperate with study requirements

    • Children with known syndromic forms of ASD caused by DNA mutation or chromosomal copy number variation

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 PaxMedica Tarrytown New York United States 10591

    Sponsors and Collaborators

    • Paxmedica

    Investigators

    • Study Director: jennifer L bonfrisco, Paxmedica

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Paxmedica
    ClinicalTrials.gov Identifier:
    NCT06058962
    Other Study ID Numbers:
    • PUR-ONQ-ASD-001
    First Posted:
    Sep 28, 2023
    Last Update Posted:
    Sep 28, 2023
    Last Verified:
    Sep 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Autism Spectrum Disorder
    Suramin

    Study Results

    No Results Posted as of Sep 28, 2023